JPMorgan raised the firm’s price target on CVS Health (CVS) to $101 from $93 and keeps an Overweight rating on the shares. The firm adjusted targets in the healthcare services group as part of its 2026 outlook. JPMorgan sees “some reasons for optimism that managed care estimates are approaching trough levels.” Most managed care companies will reach a trough in earnings in 2026 or have already reached a trough in earnings in 2025 with the potential for upward revisions going forward, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS: